Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change reported is a reduction in shareholding by a senior executive:
- Individual: Mr J R Stéphenne
- Transaction: Sale of 15,000 Ordinary shares
- Price: £13.20 per share
- Date: May 17, 2011
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total shareholding of Mr J R Stéphenne following the sale of 15,000 shares.
- Confirm the market price of GSK Ordinary shares on May 17, 2011, to contextualize the £13.20 transaction price.
- Review the company's annual report (Form 20-F) for comprehensive financial data, as this 6-K contains only transactional details.